Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $32

Benzinga · 11/07/2025 15:05
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $35 to $32.